Skip to content
Screener

Design Therapeutics, Inc. DSGN Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue-
EPS-$0.34Miss by $0.02
EPS estimate-$0.32

Next report

Nov 4, 2026 (in 2 months)
EPS estimate-$0.38

Financials

Q2 2025

Income statement

See full
Revenue-—
Operating income-$21.6M-43.4%
Net income-$19.1M-61.8%
EPS (diluted)-$0.34-61.9%

Balance sheet

See full
Cash & equivalents$19.7M-56.9%
Total debt$1.9M-28.0%
Total equity$213.0M-18.5%
Total assets$222.9M-17.3%

Cash flow

See full
Operating cash flow-$14.4M-28.3%
CapEx$87.0K-46.0%
Free cash flow-$14.5M-27.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$225.37M+19.1%
Enterprise value$207.61M+42.0%

Returns & leverage

See full
Return on equity-26.8%+24.6pp
Debt / equity0×0.0×
Current ratio25.1×-16.3×

FAQ

When did Design Therapeutics, Inc. report Q2 2025 earnings?
Design Therapeutics, Inc. (DSGN) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Design Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Design Therapeutics, Inc. reported revenue of - and eps of $-0.34 for Q2 2025.
Did Design Therapeutics, Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.32 by $0.02.
How did Design Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 61.9% from $-0.21.
Where can I find Design Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105008) and the 10-Q periodic report (0000950170-25-105062) directly on SEC EDGAR. The filing index links above go to sec.gov.